{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:31:36Z","timestamp":1790872296716,"version":"4.1.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Diffuse alveolar haemorrhage (DAH) is a rare and severe complication of IgA vasculitis (IgAV). Although glucocorticoids and immunosuppressive agents are used for its treatment, there is no consensus on the optimal form of treatment. We herein report the case of a 53-year-old, female patient with IgAV. She was initially resistant to glucocorticoid therapy and experienced acute respiratory failure due to DAH but responded well to rituximab (RTX) and plasma exchange (PLEX). While some previous case reports have suggested that RTX or PLEX can be effective for severe IgAV, there are no reports of a combination of RTX and PLEX being used successfully to treat IgAV-associated DAH. In the model of IgAV pathogenesis proposed herein, aberrant IgA1 and IgA-specific IgG autoantibodies play a pivotal role. PLEX may facilitate the prompt removal of these circulating, aberrant immunoglobulins while RTX inhibits their further production. Consequently, a combination of RTX and PLEX may represent an effective treatment approach for severe glucocorticoid-refractory cases of IgAV.<\/jats:p>","DOI":"10.1093\/mrcr\/rxae087","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T07:26:20Z","timestamp":1734420380000},"source":"Crossref","is-referenced-by-count":1,"title":["A case of glucocorticoid-refractory IgA vasculitis with diffuse alveolar haemorrhage: A therapeutic strategy for aberrant immunoglobulin depletion"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5648-1921","authenticated-orcid":false,"given":"Kazuhiko","family":"Hirokawa","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Tokyo Bay Urayasu Ichikawa Medical Center , Chiba,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Tokyo Bay Urayasu Ichikawa Medical Center , Chiba,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Hiraoka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Tokyo Bay Urayasu Ichikawa Medical Center , Chiba,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7165-7179","authenticated-orcid":false,"given":"Keiichi","family":"Iwanami","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tokyo Bay Urayasu Ichikawa Medical Center , Chiba,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"2025080201014922500_R1","first-page":"1151","article-title":"Pulmonary involvement in Henoch-Sch\u00f6nlein purpura","volume":"79","author":"Nadrous","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"2025080201014922500_R2","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1097\/01.ASN.0000013883.99976.22","article-title":"Henoch-Sch\u00f6nlein purpura in adults: outcome and prognostic factors","volume":"13","author":"Pillebout","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"2025080201014922500_R3","first-page":"S26","article-title":"Henoch-Sch\u00f6nlein\u2019s purpura in adults versus children\/adolescents: a comparative study","volume":"24","author":"Uppal","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"2025080201014922500_R4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.semarthrit.2012.07.004","article-title":"Pulmonary hemorrhage in Henoch-Sch\u00f6nlein purpura: case report and systematic review of the English literature","volume":"42","author":"Rajagopala","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"2025080201014922500_R5","first-page":"697","article-title":"Henoch-Sch\u00f6nlein purpura","volume":"80","author":"Reamy","year":"2009","journal-title":"Am Fam Physician"},{"key":"2025080201014922500_R6","first-page":"229","article-title":"Henoch-Sch\u00f6nlein purpura (IgA Vasculitis): rapid evidence review","volume":"102","author":"Reamy","year":"2020","journal-title":"Am Fam Physician"},{"key":"2025080201014922500_R7","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211059610","article-title":"Consensus evidence-based recommendations for treat-to-target management of immunoglobulin a vasculitis","volume":"13","author":"Abu-Zaid","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025080201014922500_R8","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/rheumatology\/kez041","article-title":"European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative","volume":"58","author":"Ozen","year":"2019","journal-title":"Rheumatology"},{"key":"2025080201014922500_R9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ki.2010.150","article-title":"Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Sch\u00f6nlein Purpura","volume":"78","author":"Pillebout","year":"2010","journal-title":"Kidney Int"},{"key":"2025080201014922500_R10","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/acr.20605","article-title":"Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener\u2019s)","volume":"63","author":"Clowse","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2025080201014922500_R11","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/annrheumdis-2016-209925","article-title":"Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis","volume":"76","author":"van Daalen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025080201014922500_R12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"2025080201014922500_R13","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"American college of rheumatology\/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025080201014922500_R14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025080201014922500_R15","doi-asserted-by":"crossref","DOI":"10.1186\/cc11304","article-title":"Clinical review: serious adverse events associated with the use of rituximab - a critical care perspective","volume":"16","author":"Kasi","year":"2012","journal-title":"Crit Care"},{"key":"2025080201014922500_R16","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102490","article-title":"Rituximab treatment for IgA vasculitis: a systematic review","volume":"19","author":"Hern\u00e1ndez-Rodr\u00edguez","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2025080201014922500_R17","article-title":"Successful rituximab therapy in adult-onset IgA vasculitis with diffuse alveolar hemorrhage and renal failure: a case report","volume":"8","author":"Ghebranious","year":"2023","journal-title":"AME Case Rep"},{"key":"2025080201014922500_R18","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1053\/j.ajkd.2011.12.015","article-title":"Addition of plasma exchange to glucocorticosteroids for the treatment of severe Henoch-Sch\u00f6nlein purpura in adults: a case series","volume":"59","author":"Augusto","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2025080201014922500_R19","article-title":"Efficacy and safety of plasma exchange as an adjunctive therapy for rapidly progressive IgA Nephropathy and Henoch-Sch\u00f6nlein Purpura nephritis: a systematic review","volume":"24","author":"Nguyen","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025080201014922500_R20","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.2169\/internalmedicine.0817-18","article-title":"Pulmonary hemorrhaging as a fatal complication of IgA vasculitis","volume":"57","author":"Miyoshi","year":"2018","journal-title":"Intern Med"},{"key":"2025080201014922500_R21","article-title":"IgA vasculitis update: epidemiology, pathogenesis, and biomarkers","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"key":"2025080201014922500_R22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.771619","article-title":"Pathogenesis of IgA vasculitis: an up-to-date review","volume":"12","author":"Song","year":"2021","journal-title":"Front Immunol"},{"key":"2025080201014922500_R23","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.autrev.2017.10.009","article-title":"New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Sch\u00f6nlein purpura)","volume":"16","author":"Heineke","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2025080201014922500_R24","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM197112302852701","article-title":"Effect of cyclophosphamide upon the immune response in Wegener\u2019s granulomatosis","volume":"285","author":"Fauci","year":"1971","journal-title":"N Engl J Med"},{"key":"2025080201014922500_R25","article-title":"Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis","volume":"14","author":"Gomez Mendez","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025080201014922500_R26","first-page":"634","article-title":"The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin","volume":"112","author":"Mankarious","year":"1988","journal-title":"J Lab Clin Med"},{"key":"2025080201014922500_R27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.molimm.2015.09.005","article-title":"IgA as therapeutic antibody","volume":"68","author":"Leusen","year":"2015","journal-title":"Mol Immunol"},{"key":"2025080201014922500_R28","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2020.102992","article-title":"Role of therapeutic plasma exchanges in systemic vasculitis","volume":"59","author":"R\u00e9gent","year":"2020","journal-title":"Transfus Apher Sci"},{"key":"2025080201014922500_R29","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/1744-9987.12465","article-title":"Removal dynamics of immunoglobulin and fibrinogen by conventional plasma exchange, selective plasma exchange, and a combination of the two","volume":"20","author":"Miyamoto","year":"2016","journal-title":"Ther Apher Dial"},{"key":"2025080201014922500_R30","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1053\/j.ajkd.2022.10.017","article-title":"Therapeutic plasma exchange: core curriculum 2023","volume":"81","author":"Cervantes","year":"2023","journal-title":"Am J Kidney Dis"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxae087\/61234610\/rxae087.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxae087\/61234610\/rxae087.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxae087\/61234610\/rxae087.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T05:02:26Z","timestamp":1754110946000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/doi\/10.1093\/mrcr\/rxae087\/7928437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7,25]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxae087","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2024,12,19]]},"article-number":"rxae087"}}